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year or $49.0M/year nationally. ConClusions: Differences in study design should 
be addressed when conducting an ITC. The evidence from this ITC shows that abira-
terone and enzalutamide have similar efficacy in OS in mCRPC post chemotherapy. 
However, abiraterone is cost saving compared to enzalutamide in this analysis.
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DiffereNCes iN MeDiCal Cost aND survival BetweeN trial aND NoN-
trial PatieNts with aCute MyeloiD leukaeMia – a uk PoPulatioN-
BaseD ProPeNsity aNalysis
Wang H.I.1, Aas E.2, Roman E.1, Howell D.1, Painter D.1, Smith A.1
1University of York, York, UK, 2University of Oslo, Oslo, Norway
objeCtives: Information about acute myeloid leukaemia (AML), including the 
costs of treatment and survival-estimates, are usually derived from clinical trial 
data. However, it is not known whether this information is generalizable to non-
trial patients. This study was carried out to evaluate the differences in medical costs 
and survival between trial and non-trial patients with AML; and hence assess the 
external validity of trial data to the general patient population. Methods: The 
Haematological Malignancy Research Network (HMRN, www.hmrn.org) is an estab-
lished population-based patient cohort that registers around 2000 newly diagnosed 
patients each year. All adults (≥ 18) newly diagnosed with AML between September 
2004 and August 2007 and treated with induction intent were included. Patients were 
followed until August 2012, and the comparative outcomes were medical costs and 
survival. Standard statistical analyses were used to measure unadjusted difference 
in outcomes, and propensity score analyses were applied to measure differences by 
adjusting for baseline imbalance in pre-treatment characteristics between trial and 
non-trial patients. Results: Overall, 173 patients treated with induction intent were 
included, of which 106 were trial and 67 non-trial. Trial participation was associated 
with younger age, fewer comorbidities, better prognosis, and being treated at teach-
ing hospitals. Before controlling for patients’ characteristics, trial patients had better 
survival and incurred higher costs (p< .0001 for both). After controlling for patients’ 
characteristics by carrying out propensity score analyses, these differences remained 
significant in both survival (median survival 28.7 vs. 8 months; p< .0001) and medical 
costs (mean costs £84,497 vs. £49,624; p< .0001). ConClusions: For AML patients 
treated with induction intent, significant differences were observed in treatment costs 
and survival according to trial status, both before and after controlling for patients’ 
pre-treatment characteristics. Data generated solely from clinical trials may therefore 
not be generalizable to non-trial patients and should be treated with some caution 
when used to facilitate decision-making.
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the effeCt of Positive MargiNs oN outCoMes iN Breast CaNCer
Ling C.S.1, Weisgerber-Kriegl U.M.2, Njue A.1, Heyes A.E.1, Kaye J.A.3
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objeCtives: To review the data available on excision margins following breast-
conserving therapy (BCT), focusing on definitions of positive and clear margins, per-
centage of operations resulting in positive margins, the effect of positive margins on 
future treatment, and the relationship between positive margins and disease-free 
and overall survival. Methods: Targeted searches of PubMed were conducted using 
a predefined search strategy. Data from robust systematic reviews and/or meta-anal-
yses were given priority. Results: Definitions of positive and negative margins are 
variable, but typically a clear margin of 2 mm is considered acceptable. Most studies 
indicate positive margins in 20%-40% of patients after wide local excision. Guidelines 
recommend that patients with positive margins after BCT undergo repeat surgery, 
and in surveys, most physicians said they would recommend re-excision when there 
is tumour within 1 mm of the margin. In the identified studies, 20%-30% of patients 
underwent re-excision and approximately 2% had multiple re-excisions (two or more); 
10%-15% of patients who initially had lumpectomy later had a mastectomy. There 
is a significant association between margin status and local recurrence (in a recent 
meta-analysis, the odds ratio was 2.42 for positive vs. negative margin status; 95% 
confidence interval, 1.94-3.02; P< 0.001). However, among patients with a clear margin, 
width is not clearly related to risk of local recurrence. Four studies that assessed the 
effect of margin status on overall or disease-specific survival were identified, three 
reported a significant association (e.g., cause-specific survival at 12 years significantly 
associated with margin status, P< 0.001). ConClusions: Definition of adequate mar-
gins remains controversial. None-the-less, final margin status is a key prognostic 
factor following BCT. The data identified suggest that an intervention that reduces 
the rates of positive margins during BCT may have the potential to improve outcomes 
and reduce the burden on patients and health care providers.
PCN17
a MixeD treatMeNt CoMParisoN (MtC) to CoMPare ProgressioN free 
survival (Pfs) assoCiateD with DiffereNt CheMotheraPy regiMeNs 
for PlatiNuM-seNsitive or Partially PlatiNuM-seNsitive reCurreNt 
aDvaNCeD ovariaN CaNCer
Edwards S.J., Barton S., Thurgar E., Wakefield V., Karner C., Trevor N.
BMJ Group, London, UK
objeCtives: This research was conducted during a review of the manufacturer’s 
submission (MS) to the NICE Single Technology Appraisal programme for beva-
cizumab, a vascular endothelial growth factor (VEGF) inhibitor. Bevacizumab in 
combination with gemcitabine/carboplatin has recently been licensed for use in 
patients with platinum-sensitive or partially platinum-sensitive recurrent advanced 
ovarian cancer. This research compared this new triple therapy with treatments 
used in clinical practice in the UK: platinum monotherapy, gemcitabine/carboplatin, 
paclitaxel/carboplatin, pegylated liposomal doxorubicin hydrochloride (PLDH)/car-
boplatin. Methods: Randomised controlled trials (RCTs) for inclusion were identi-
fied using the MS for bevacizumab. RCTs were assessed for comparability based on 
patient population, disease severity, platinum sensitivity, and treatments received. 
An MTC was conducted using a Bayesian Markov chain Monte Carlo simulation. 
or 500mg. The indirect analysis did not show a statistically significant difference in 
OS between everolimus compared with fulvestrant.
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sMall MoleCule targeteD theraPies for the seCoND liNe treatMeNt 
of MetastatiC reNal Cell CarCiNoMa (MrCC): a systeMatiC review 
aND iNDireCt CoMParisoN of safety aND effiCaCy
Dranitsaris G.1, Schmitz S.2, Broom R.J.3
1University of Ioannina, Ioannina, Greece, 2Trinity College, Dublin, Ireland, 3Auckland City 
Hospital, Auckland, New Zealand
objeCtives: Patients with mRCC and a good performance status typically receive 
an anti-VEGFR TKI (sunitinib or pazopanib) as initial therapy. Upon disease progres-
sion or intolerance, there are four orally-administered agents approved in the 2nd 
- line setting (including cytokine-refractory). However, head to head comparative 
trial data are limited. In the absence of such data, mixed treatment comparison 
(MTC) models are a widely accepted statistical method for generating comparative 
effectiveness information. In this study, an indirect comparison on the safety and 
efficacy was undertaken between axitinib, sorafenib, pazopanib and everolimus 
for 2nd - line therapy in advanced RCC. Methods: A systematic review of major 
databases was conducted from January 2005 to June 2013 for randomized controlled 
trials evaluating at least one of the four agents in 2nd- line mRCC. Bayesian MTC 
models were fitted to assess comparative effectiveness based on multiple endpoints: 
tumour response, progression free survival (PFS), grade III/IV toxicities such as diar-
rhea, fatigue, hand foot skin reaction, rash and stomatitis as well as treatment 
discontinuations. Results: A total of four randomized trials meeting the inclusion 
criteria were appropriate for the statistical pooling exercise. All four agents seem 
able to induce tumour shrinkage and provide patients with a clinically meaningful 
PFS benefit. Axitinib was superior to pazopanib (HR = 0.64; 95%Crl: 0.42 to 0.96) and 
sorafenib (HR = 0.70; 95%Crl: 0.57 to 0.87) in terms of PFS. However, patients receiv-
ing axitinib would be at an elevated risk for fatigue and to a lesser extent, stoma-
titis. ConClusions: Keeping in the mind the caveats associated with cross-trial 
comparisons, axitinib appears to provide superior PFS benefits relative to pazopanib 
and sorafenib. However, this is at a cost of a higher frequency of some dose-limiting 
toxicities. Everolimus, an mTor inhibitor, is mechanistically distinct from the other 
agents evaluated and would be a useful option post anti-VEGFR TKI failure.
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targeteD theraPy iN triPle-Negative MetastatiC Breast CaNCer 
(tNBC) - a systeMatiC review aND Meta-aNalysis
Clark O.A.C.1, Engel T.1, Paladini L.1, Ferreira M.B.A.2
1Evidencias, Campinas, Brazil, 2Roche, São Paulo, Brazil
objeCtives: To perform a systematic review and meta-analysis of all randomized 
controlled trials comparing the efficacy of targeted therapy to conventional CT in 
patients with metastatic Triple-Negative Breast Cancer (TNBC). Methods: Several 
databases were searched, including MEDLINE, EMBASE, LILACS, and CENTRAL. The 
primary endpoint was progression-free survival (PFS). We performed a meta-analysis 
(MA) of the published data. The results were expressed as Hazard Ratio (HR) or Risk 
Ratio (RR), with their corresponding 95% confidence intervals (CI 95%). Results: 
The final analysis included 12 trials comprising 2,054 patients with TNBC. It was 
evidenced studies with conventional CT plus targeted therapy including bevacizumab 
(Bev), sorafenib (Sor), cetuximab and iniparib. The PFS was higher in patients who 
received Bev plus CT compared to CT alone in previously untreated patients with 
TNBC (fixed effect: HR= 0.62; CI 95%= 0.51-0.75; p< 0.00001). The PFS was also higher 
in one study with Bev plus CT in previously treated patients (fixed effect: HR= 0.49; 
CI 95%= 0.33-0.74; p= 0.0006). Sor plus CT was available in first-line and second-line. 
The PFS was higher in the group with Sor versus CT alone (fixed effect: HR= 0.69; CI 
95%= 0.49-0.98; p= 0.04) and iniparib plus CT (fixed effect: HR= 0.75; CI 95%= 0.62-0.90; 
p= 0.002). ConClusions: Bev, Sor and iniparib, when associated with the conven-
tional CT, demonstrated gains in the PFS of patients with TNBC.
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aBirateroNe aND eNzalutaMiDe for the treatMeNt of MetastatiC 
CastratioN-resistaNt Prostate CaNCer (MCrPC) Post CheMotheraPy: 
aN iNDireCt CoMParisoN aND BuDget iMPaCt aNalysis
Li T.1, Thompson M.2, Todd M.1, Yu M.1, Kheoh T.1, Saadi R.1
1Janssen Global Services LLC, Raritan, NJ, USA, 2Cornerstone Research Group, Burlington, ON, 
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objeCtives: Abiraterone and enzalutamide are two new treatment options for 
patients with mCRPC after docetaxel-based chemotherapy. This study aims to 
understand the relative clinical and economic value of these therapies. Methods: 
Two pivotal clinical trials were conducted to evaluate abiraterone and enzalutamide 
in post-docetaxel treatment of mCRPC: Study COU-AA-301 for abiraterone and the 
AFFIRM trial for enzalutamide. The PICO (population, intervention, comparison, and 
outcomes) construct was employed to assess the comparability of the trials, followed 
by an indirect treatment comparison (ITC) using the Bucher method and a mix treat-
ment comparison using Bayesian statistics. An economic evaluation was performed 
based on the ITC results. Results: Several key differences were identified between 
the COU-AA-301 and AFFIRM trials. First, the studies used different comparators. 
Abiraterone plus prednisone was compared with prednisone alone, while enzaluta-
mide was compared with placebo. Second, the endpoints rPFS, PSA progression, and 
PSA response were defined differently between trials, and thus were not included in 
the analysis. To address the difference in comparators, the ITC was performed using 
data from COU-AA-301 and subjects receiving corticosteroids concurrently in the 
AFFIRM trial. OS was significantly improved with both abiraterone and enzalutamide 
(3.9 and 3.2 months respectively). The ITC results were HR = 0.949 (95% CI: 0.712-1.26) 
for abiraterone versus enzalutamide using the Bucher method, and HR = 0.948 (95% CI: 
0.711-1.26) using the Bayesian method. Using the US price for abiraterone and enza-
lutamide (approved in the US only), and assuming 25% of patients received therapy 
following docetaxel, cost savings from using abiraterone would be > $10K/patient/
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months. Methods: In PRIME, 1183 patients with previously untreated mCRC 
were randomised. Using data from an exploratory analysis conducted when 80% 
of patients had died, NNTs (Bender. Encyclopedia of Biostatistics, Second Edition; 
Volume 6, pp3752-61) were retrospectively calculated in patients with KRAS/NRAS 
WT (n= 505; exons 2-4 assessed) mCRC overall and in the ECOG performance score 
0/1 (n= 473) subgroup. ORR and PFS events were defined using RECIST. Results: 
In the overall KRAS/NRAS WT population, 59.3% vs 45.6% of patients receiving 
panitumumab+FOLFOX4 vs FOLFOX4 alone, respectively, achieved an OR; NNT(95% 
CI) in the ORR analysis was 7.3(4.5-19.9). In the ECOG 0/1 subgroup, 61.3% vs 46.4% 
of those receiving panitumumab+FOLFOX4 vs FOLFOX4 alone, respectively, had an 
OR; the NNT(95% CI) was 6.7(4.2-16.5). For the PFS overall population analysis, the 
HR(95% CI) was 0.74(0.62-0.90); HR(95% CI) for the ECOG 0/1 subgroup was 0.72(0.59-
0.88). NNTs(95% CI) in the overall population at 6 and 12 months were 12.8(8.3-34.1) 
and 9.2(5.7-25.9), respectively; corresponding values for the ECOG 0/1 subgroup were 
11.9(7.9-27.8) and 8.4(5.3-20.8). For the OS overall population analysis, the HR(95% 
CI) was 0.76(0.63-0.93); HR(95% CI) for the ECOG 0/1 subgroup was 0.74(0.60-0.90). 
NNTs(95% CI) in the overall population at 12 and 24 months were 16.8(10.4-57.1) and 
10.4(6.2-37.1), respectively; corresponding values for the ECOG 0/1 subgroup were 
16.0(10.3-44.1) and 9.4(5.9-27.2). ConClusions: In these analyses NNTs for PFS, 
OS and particularly ORR were low, reflecting the high therapeutic benefit of adding 
panitumumab to FOLFOX4 in patients with KRAS/NRAS WT mCRC. Limitation by 
ECOG score 0/1 further lowered NNTs for PFS and OS.
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iNDireCt CoMParisoN aNalysis to evaluate the CliNiCal 
effeCtiveNess of trastuzuMaB eMtaNsiNe (t-DM1) versus other 
treatMeNts for her2-Positive MetastatiC Breast CaNCer (MBC)
Benito Garcia E.1, Hersberger V.1, Takyar S.2, Moser A.1
1F. Hoffmann-La Roche Ltd., Basel, Switzerland, 2Heron Health, Chandigarh, India
objeCtives: T-DM1, an antibody-drug conjugate which combines the antitumor 
properties of trastuzumab (H) with the cytotoxic agent DM1, is approved for the 
treatment of patients with MBC previously treated with trastuzumab+taxane. We 
compared the clinical effectiveness of T-DM1 versus all available therapies used in 
the treatment of unresectable HER2-positive locally advanced breast cancer (LABC) 
or MBC. Methods: This systematic review (SR) and indirect treatment comparison 
(ITC) included all published data between January 1, 1998 and December 20, 2012. 
Studies were chosen in accordance with conventional methods for performing and 
reporting SRs and ITCs (i.e., Cochrane Handbook for SRs, PRISMA, ISPOR guidelines, 
and major HTA agencies). Eligible trials were controlled trials of treatments for 
unresectable HER2-positive LABC or MBC that had progressed after treatment with 
combination of trastuzumab+taxane in the adjuvant or MBC setting. Progression 
had to have occurred after the most recent treatment for LABC or MBC or within 6 
months after treatment for early-stage disease. Results: Seven RCTs and two non-
randomized controlled trials (n-RCTs) met the inclusion criteria. Of the seven RCTs, 
five had a common comparator, being eligible for the ITC. The other two RCTs and 
two n-RCTs did not have a common comparator and were thus not included in the 
ITC. T-DM1 was the only treatment to demonstrate statistically significantly longer 
overall survival (OS) and progression-free survival (PFS) when directly compared to 
capecitabine+lapatinib, and when indirectly compared to capecitabine+trastuzumab 
(PFS HR [95% CI]: 0.53 [0.32, 0.86], p= 0.01; OS HR [95% CI]: 0.56 [0.35, 0.91]; p= 0.01) 
and capecitabine monotherapy (PFS HR [95% CI]: 0.36 [0.25, 0.51]; p< 0.0001); OS (HR 
[95% CI]: 0.53 (0.39, 0.72); p= 0.0009). ConClusions: In this ITC, T-DM1 was associ-
ated with longer OS and PFS versus capecitabine+trastuzumab and capecitabine 
monotherapy in patients with HER2-positive LABC or MBC with disease progression 
after treatment with trastuzumab+taxane.
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seCoND-liNe treatMeNt of MetastatiC ColoreCtal CaNCer (MCrC): a 
systeMatiC literature review (slr) aND feasiBility assessMeNt of 
CoNDuCtiNg iNDireCt treatMeNt CoMParisoN (itC) aNalysis
Xu Y.1, Martin A.L.1, Ross S.2, Knopf K.B.3, Strand L.1, Iqbal S.U.4, Joulain F.5,  
Jasso Mosqueda J.G.6, Fahrbach K.1
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objeCtives: To investigate the efficacy and safety of second-line chemotherapy in 
mCRC and to determine the feasibility of relative efficacy between treatments using 
indirect or mixed treatment comparisons. Methods: An SLR on randomized trials 
published from 1992–2012 was performed. EMBASE, PubMed, CENTRAL databases 
were consulted. Manual searches (including ASCO and ESMO abstracts) were also 
conducted. Eligible studies evaluated second-line clinical efficacy and safety end-
points in mCRC. Results: Twenty-seven trials with patients enrolled ranging from 
n= 33–1,226 were identified. Patients were markedly diverse in terms of ECOG, EGFR, 
or KRAS status, and prior treatment exposures: oxaliplatin (k= 9), irinotecan +/- 5-FU 
(k= 5), bevacizumab (k= 7), and 5-FU (k= 22). On-study treatments and comparators 
were also diverse: FOLFIRI alone (t= 6) or with panitumumab (t= 2) or aflibercept 
(t= 1); FOLFOX4 alone (t= 6) or with bevacizumab (t= 1); bevacizumab alone (t= 1) or 
with chemotherapy (t= 2); irinotecan alone (t= 19) or with FOLFOX4 (t= 2) or cetuxi-
mab (t= 1); and miscellaneous other regimens (t= 19). Study methodologies varied 
in analysis populations (ITT [k= 24] vs. per protocol or not reported [k= 3]), primary 
efficacy outcomes (OS, PFS, and/or tumor response, as variably measured), follow-up 
durations, and timing of outcomes measurements. Preliminary network diagrams to 
assess feasibility of meta-analyses for ITC revealed only a single study for each treat-
ment comparison of interest. Assumptions of comparability of apparently diverse 
patients, past and current treatment regimens, and comparator arms would be 
necessary to pool treatment groups for meta-analysis of treatment effectiveness 
across studies and hence, is not feasible. Given the lack of SOC treatments used in 
many trials, introducing such assumptions will compromise the evidence-based 
criteria for quantitative clinical data syntheses for indirect or mixed treatment 
Fixed and random effects models were explored with results reported for the best 
fitting model. Hazard ratio (HR) was chosen as the summary statistic. Results: The 
network of 6 RCTs formed a linear series of “steps”, which facilitated comparison of 
all chemotherapy regimens of interest. The fixed effects model was the best-fitting 
model. There was reasonable agreement between the number of unconstrained 
data points, residual deviance and pair-wise results, suggesting a coherent network. 
Using bevacizumab/gemcitabine/carboplatin as the baseline, the results for PFS 
for the other chemotherapy regimens were: platinum monotherapy (HR 2.92, 95% 
Credible Interval [CrI]: 2.10 to 3.96), gemcitabine/carboplatin (HR 2.09, 95% CrI: 1.65 
to 2.60), paclitaxel/carboplatin (HR 2.16, 95% CrI: 1.50 to 3.01), PLDH/carboplatin (HR 
1.77, 95% CrI: 1.20 to 2.51); where a HR> 1 favours bevacizumab/gemcitabine/carbo-
platin and a HR< 1 favours the comparator. ConClusions: This research suggests 
bevacizumab in combination with gemcitabine/carboplatin may offer significantly 
longer PFS compared with other chemotherapy options available in the UK.
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effiCaCy of BreNtuxiMaB veDotiN aND other treatMeNts iN PatieNts 
with relaPseD or refraCtory (rr) systeMiC aNaPlastiC large-Cell 
lyMPhoMa (salCl): a systeMatiC review
Bonthapally V.1, Yang H.2, Macalalad A.R.2, Wu E.Q.2, Lutes R.3, Shonukan O.1, Chi A.3, Huebner 
D.3
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objeCtives: Brentuximab vedotin (ADCETRIS®), a CD30-targeted antibody-drug 
conjugate, has conditional approval in Europe for the treatment of adult patients 
with RR sALCL. This systematic review summarized the efficacy of other treatments 
for RR ALCL, for comparison with brentuximab vedotin. Methods: A systematic 
literature review identified studies published between 1993 and February 2013 report-
ing efficacy of treatments in adult patients with RR ALCL, or more generally with RR 
peripheral T-cell lymphoma (PTCL) including ≥ 1 ALCL patient. Five databases were 
included: EMBASE, MEDLINE, and the WHO ICTRP; reviews published since 2011 were 
also searched manually for additional studies. English publications reporting com-
plete remission/response (CR) rate and/or 2-year overall survival (OS) in RR ALCL/
PTCL populations were included. Publications of principal treatment with bone mar-
row transplantation or radiotherapy were excluded. CR rates and 2-year OS, from 
the identified studies and from the brentuximab vedotin single-arm phase 2 trial 
in sALCL (SG035-0004), were summarized. Results: Of 1653 publications screened, 
12 studies were eligible for inclusion; all were phase 1 or 2 or unspecified prospec-
tive non-randomized studies. For these studies, the CR rates were 0–28% in RR PTCL 
patients (n= 4–130 PTCL; median age 36–69 years; n= 1–41 ALCL), and for the 6 studies 
that also reported CR outcomes in the subset of RR ALCL patients (n= 13–130 PTCL; 
median age 47–69 years; n= 2–41 ALCL), the CR rates were 0–33% in RR ALCL patients. 
For RR ALCL patients treated with brentuximab vedotin in SG035-0004 (n= 58 sALCL; 
median age 52 years) the CR rate was 59%. The 2-year OS ranged from 7–33% in the 
5 identified studies that reported OS, compared with 63% with brentuximab vedotin 
in SG035-0004. ConClusions: The CR rate and 2-year OS for brentuximab vedotin 
in RR sALCL appear to exceed that of other therapies in RR ALCL/PTCL.
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a CoMMuNity-BaseD, Case-CoNtrol stuDy evaluatiNg Mortality 
reDuCtioN froM gastriC CaNCer By eNDosCoPiC sCreeNiNg iN JaPaN
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objeCtives: Although gastric cancer has decreased in the last three decades, it is 
still the second leading cause of cancer death worldwide. In Asian countries, the 
burden of gastric cancer has remained, and screening is still expected to prevent 
gastric cancer death. In order to evaluate reduction of mortality from gastric cancer 
by endoscopic screening, a community-based, case-control study was conducted in 
Japan. Methods: Case subjects were defined as persons who had died of gastric 
cancer between 2003 and 2006 in four cities, Tottori Prefecture, and between 2006 
and 2010 in Niigata City, Japan. Up to six control subjects were matched by sex, birth 
year (±3 years), and residence of each corresponding case from population lists in the 
study areas. Controls were required to be disease-free at the time when the case was 
diagnosed gastric cancer. The odds ratios were calculated for those who had ever par-
ticipated in endoscopic screening or radiographic screening before the reference date 
when the case was diagnosed gastric cancer, compared with persons who had never 
participated in any screening. Conditional logistic-regression models for matched sets 
were used to estimate the odds ratios and 95% confidence intervals. Results: There 
were 288 males and 122 females for case subjects, with 2,292 matched control subjects. 
Compared with those who had never been screened before the date of diagnosis of 
gastric cancer in cases, the odds ratios within 48 months from the diagnosis date 
were 0.703 (95% confidence interval :0.497-0.996) for endoscopic screening and 0.860 
(95% confidence interval :0.631-1.171) for radiographic screening. ConClusions: The 
result suggests a 30% reduction from gastric cancer mortality by endoscopic screening 
compared to no screening within 48 months before the diagnosis date of gastric cancer.
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BeNefit of aDDiNg PaNituMuMaB to folfox4 iN PatieNts with kras/
Nras wilD-tyPe (wt) MetastatiC ColoreCtal CaNCer (MCrC): a NuMBer-
NeeDeD-to-treat (NNt) aNalysis
Douillard J.Y.1, Sienna S.2, Davison C.3, Braun S.4, Sidhu R.5
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Oaks, CA, USA
objeCtives: To calculate NNTs for panitumumab+FOLFOX4 vs FOLFOX4 alone 
(PRIME study) to achieve one objective response (OR rate [ORR] analysis) or pre-
vent one disease progression (PFS analysis) or death (OS analysis) at 6/12 or 12/24 
